-
Prolia – Hypocalcemia Side Effect Safety Signal May Draw Regulatory Action by FDA
"Risk of severe hypocalcemia" in Patients on Dialysis Receiving Osteoporosis Drug Prolia (denosumab) (Posted by Tom Lamb at Drug Injury Watch) The FDA is in the process of evaluating the osteoporosis drug Prolia (denosumab) to…
-
Artificial Tears Vision Loss Case Reports Published in March 2023 Medical Journal
JAMA Ophthalmology Articles Give Details About Serious Eye Infections Due to Use of EzriCare Eye Drops (Posted by Tom Lamb at Drug Injury Watch) Two recent JAMA Ophthalmology medical journal articles presented a detailed EzriCare…
-
New Reporting System for Cases of Breast Implant-Associated Lymphoma: PROFILE Registry
March 2023 Miami Breast Cancer Conference: Updates on The Number of BIA-ALCL Deaths and Diagnoses (Posted by Tom Lamb at Drug Injury Watch) In late March 2023, the FDA issued an update that announced the…
-
February Recalls of Eye Products Due to Bacterial Contamination Causing Serious Infections
Timeline for EzriCare Artificial Tears, Delsam Pharma’s Artificial Tears, Delsam Pharma’s Artificial Eye Ointment (Posted by Tom Lamb at Drug Injury Watch) During February 2023 there were recalls of Global Pharma eye products, specifically: EzriCare…
-
Delsam Pharma’s Artificial Eye Ointment Recalled, Weeks After Artificial Tears Products Withdrawal
Updates About Bacterial Contamination Problem for These Over-The-Counter (OTC) Eye Products Given by FDA and CDC (Posted by Tom Lamb at Drug Injury Watch) On February 21, 2023, and February 22, 2023, there were updates…
-
Artificial Tears Eye Drops Recall Involving EzriCare and Delsam Pharma’s Products in February 2023
Serious Infections Causing Vision Loss Have Been Linked to the Use of EzriCare Artificial Tears Lubricant Eye Drops (Posted by Tom Lamb at Drug Injury Watch) Today we pick up where our article from last…